Have you ever asked a patient, “How’s your sex life?” If your answer is “No,” you’re not alone. The Centers for Disease Control and Prevention (CDC) finds healthcare providers don’t talk about sex with their patients for a variety of reasons: They feel uncomfortable discussing sex and sexuality with patients; They believe discussing sex will…
A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.
ACR CONVERGENCE 2020—Research has shown time and again the benefits and low risk of physical activity for people with rheumatic diseases, but only a third or less of patients meet guidelines for this activity, Patricia Katz, PhD, professor of medicine and health policy at the University of California, San Francisco, said in the ARP Distinguished…
In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.
In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.
In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.
Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.
It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…
According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).
Although systemic lupus erythematosus (SLE) affects both the central nervous system (CNS) and peripheral nervous system (PNS), past research has primarily focused on how lupus affects the CNS. Now, an international, inception cohort study, “Peripheral Nervous System Disease in Systemic Lupus Erythematosus,” published in Arthritis & Rheumatology, has examined different types of PNS disease to…